Tritax Big Box to buy rival Warehouse in £485m deal
Tritax Big Box has agreed a £485.2 million deal to buy a London-listed rival, fending off a competing bid by private equity giant Blackstone.
Warehouse REIT (Real Estate Investment Trust) said on Wednesday its bosses have recommended the proposed takeover by Tritax.
The deal will value Warehouse – which owns a raft of distribution sites run by companies including Amazon – at 114.2p per share.
It comes weeks after Warehouse originally agreed to be bought by US private equity firm Blackstone for £470 million.
Warehouse shares jumped in early trading after it confirmed the new takeover plan.
Bosses at Tritax said the deal 'has a compelling strategic and financial rationale' for shareholders in both companies.
The firms said the move would deliver £5.5 million a year in immediate cost synergies due to larger economies of scale.
Aubrey Adams, the chairman of Tritax Big Box, said: 'This transaction delivers value accretion to both Tritax Big Box and Warehouse shareholders driven by immediate cost synergies, rental reversion and strong structural drivers supporting valuation and income growth in urban and big box logistics.
'The board is delighted to be able to offer Warehouse shareholders the opportunity to be invested in the upside potential of the UK's leading listed logistics real estate portfolio, whilst also providing the certainty of a partial cash offer.'
Neil Kirton, the chairman of Warehouse, said: 'The board is pleased to be recommending the acquisition, which is not only at a higher level to the previous offer for the company, but which also provides Warehouse shareholders with the opportunity to retain both the Warehouse Q4 and Q1 dividends and remain invested in this attractive asset class.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
26 minutes ago
- Daily Mail
Wood Group takeover talks extended again amid regulatory probe
John Wood Group has again extended the deadline for suitor Sidara to make a concrete takeover offer for the company. It follows the launch of a City watchdog investigation into Wood Group last week after an independent review unearthed 'cultural failings' with its accounting practices. The North Sea-focused oilfield services provider told investors on Monday Dubai-based Sidara now has until 5pm on 28 July to put forward a 'put up or shut up' proposal, having originally given the firm until today to do so. Sidara began a fresh move for Wood Group in February after a previous attempt to acquire the company in a £1.7billion deal last year failed. However, Wood Group refused to accept the offer after two months of talks, blaming 'rising geopolitical risks and financial market uncertainty'. Sidara eventually put forward a far lower 35p per share bid in April, which values Wood Group at around £240million. The offer additionally includes a potential $450million capital injection and Wood Group possibly pursuing an extension or amendment to its current debt facilities. Wood Group shares have plummeted by approximately 84 per cent over the past year amidst cash flow problems, massive contract write-offs and accounting failures. In February, the Edinburgh-based firm warned that it expected between $150million and $200million in negative free cash flow this year owing to subdued trading and legacy claims liabilities totalling about $150million. Its chief financial officer, Arvind Balan, resigned soon afterwards when he admitted to inaccurately describing his professional qualifications. A month later, Wood Group admitted that its previous financial statement would have to be restated after a Deloitte probe uncovered 'material weaknesses and failures' in the financial culture of its projects business. Following delays in publishing its 2024 results, the company's shares were suspended from trading on the London Stock Exchange in April. And just last week, the Financial Conduct Authority (FCA) began its own investigation into Wood Group, which will look at the firm's conduct between January 2023 and November 2024. Founded as Dar al-Handasah in Lebanon in 1956, Sidara is a network of engineering and design companies employing about 21,500 people with a specialist focus on large-scale building projects. Wood Group employs 35,000 individuals across more than 60 countries who give consultation, engineering, and management services to the energy and minerals sectors. Private equity giant Apollo Global Management tried to purchase Wood Group in 2023, making four proposals, including a final offer of 240p per share, before the latter walked away without explanation.
Reuters
33 minutes ago
- Reuters
UK lenders approve more mortgages than expected in May
LONDON, June 30 (Reuters) - British lenders approved 63,032 mortgages in May, more than expected by economists, Bank of England data showed on Monday, suggesting the housing market recovered quickly from the end of a tax break for homebuyers in April. A Reuters poll of economists had pointed to 59,750 mortgage approvals during the month.
Daily Mail
34 minutes ago
- Daily Mail
UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers
Medicines firm Hikma Pharmaceuticals plans to invest $1billion into US manufacturing and research and development over the next five years. The London-headquartered firm told investors on Monday the investment would expand its domestic capabilities 'to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide'. Hikma specialises in generic medicines - medications created to be the same as a brand-name drug, but usually sold at a lower cost. It comes as the UK-US trade deal comes into effect today, leaving UK carmakers with reduced tariffs of 10 per cent and removing levies on the aerospace sector entirely. However, Britain's pharmaceutical sector still faces the potential for further tariffs down the line, as well as recent suggestions the White House could move to clamp-down on the price of medicines in the US. UK pharma sold £6.6billion worth of products to the US last year, meaning the sector is Britain's second-biggest export to the country. President Donald Trump's threat to end exemptions on pharma tariffs, which are driven by a 1995 World Trade Organisation deal, has sparked fears that disruption to the sector's highly complex supply chain could have implications for UK pharmacies and patients. Hikma said on Monday it has provided access 'to a wide range of generic medicines at a lower cost than branded products' since operating in the US since 1991. The group's 'America Leans on Hikma' strategy plans to increase the volume of 'essential medicines' developed and produced across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and New Jersey. Hikma said: 'This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.' President of Hikma's generics business Dr. Hafrun Fridriksdottir added: 'We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients. 'Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.'
